ABCG2 and breast carcinoma: On the other hand, using an online transcriptome-level validation tool for predictive biomarkers [52], we found that ABCG2, associated with resistance to chemo- and radiotherapy [53] and RUNX2, which has been shown to chemo-sensitize breast cancer cells to neoadjuvant therapy [43], are more highly expressed in non-responder patients.